Answer
Sacituzumab govitecan (Trodelvy) is not recommended during pregnancy because it contains the genotoxic component SN-38, targets rapidly dividing cells and, based on its mechanism of action, can cause teratogenicity and/or embryo-foetal death.
Sources for this answer
- Trodelvy 180 mg powder for concentrate for solution for infusionGilead Sciences Ltd · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 10Document updated
Sources checked